^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    epratuzumab-thorium-227 (BAY1862864)

    i
    Other names: BAY1862864, targeted thorium conjugate, thorium-227 linked to epratuzumab using targeted thorium conjugates platform, epratuzumab Th-227
    Associations

    News

    Trials
    Company:
    Bayer
    Drug class:
    Apoptosis stimulant, CD22 modulator
    Related drugs:
    Associations

    News

    Trials
    3years
    Thorium-227-Labeled Anti-CD22 Antibody (BAY 1862864) in Relapsed/Refractory CD22-Positive Non-Hodgkin Lymphoma: A First-in-Human, Phase I Study. (PubMed, Cancer Biother Radiopharm)
    BAY 1862864 was safe and tolerated in patients with R/R-NHL. The Clinical Trial Registration numbers: NCT02581878 and EudraCT 2014-004140-36.
    P1 data • Journal
    |
    CD22 (CD22 Molecule)
    |
    CD22 positive
    |
    epratuzumab-thorium-227 (BAY1862864)
    over4years
    Safety and Tolerability of BAY1862864 Injection in Subjects With Relapsed or Refractory CD22-positive Non-Hodgkin's Lymphoma (clinicaltrials.gov)
    P1, N=21, Completed, Bayer | Active, not recruiting --> Completed
    Clinical • Trial completion
    |
    CD22 (CD22 Molecule)
    |
    CD22 positive
    |
    epratuzumab-thorium-227 (BAY1862864)
    5years
    Safety and Tolerability of BAY1862864 Injection in Subjects With Relapsed or Refractory CD22-positive Non-Hodgkin's Lymphoma (clinicaltrials.gov)
    P1; N=21; Active, not recruiting; Sponsor: Bayer; Recruiting --> Active, not recruiting; N=60 --> 21; Trial completion date: Oct 2020 --> Dec 2019; Trial primary completion date: Mar 2020 --> Apr 2019
    Trial completion date • Trial primary completion date • Enrollment change • Enrollment closed • Clinical
    |
    CD22 (CD22 Molecule)
    |
    CD22 positive
    |
    epratuzumab-thorium-227 (BAY1862864)
    5years
    Safety and Tolerability of BAY1862864 Injection in Subjects With Relapsed or Refractory CD22-positive Non-Hodgkin's Lymphoma (clinicaltrials.gov)
    P1, N=60, Recruiting, Bayer | Trial completion date: Apr 2020 --> Oct 2020
    Clinical • Trial completion date
    |
    CD22 (CD22 Molecule)
    |
    CD22 positive
    |
    epratuzumab-thorium-227 (BAY1862864)